2024年发表在Circulation上的一项研究指出,在2型糖尿病和中等程度以上的白蛋白尿(尿白蛋白肌酐比值UACR≥30 mg/g)的患者中,与传统治疗相比,SGLT2i、GLP-1 RA和ns-MRA的三药联合治疗可显著降低心血管和肾脏事件的发生风险以及提高总生存率。 本研究纳...
与GLP-1受体激动剂相比,SGLT-2抑制剂-GLP-1受体激动剂联合使用可使主要不良心血管事件的风险降低30%(7.0 vs 10.3例事件/1000人年;风险比0.70,95%CI 0.49～0.99),严重肾脏事件风险降低57%(2.0 vs 4.6例事件/1000人年;风险比0.43,95%CI 0.23～0.80)。 与SGLT-2抑制剂相比,GLP-1受体激动剂-SGLT-2抑制剂联...
The SGLT2i and GLP-1 RAs also reduced macroalbuminuria, decreased the time for doubling of serum creatinine, and slowed the time to end-stage renal disease. In this perspective, we review the potential benefit of combination SGLT2i/GLP-1 RA therapy on metabolic-cardiovascular-renal disease in...
背景:SGLT-2i、GLP-1 RA和ns-MRA非奈利酮均能单独降低2型糖尿病合并蛋白尿患者的心血管、肾脏和死亡结局。然而,这些药物联合治疗的终生获益尚不清楚。 方法:使用来自两项SGLT-2i试验(CANVAS[卡格列净心血管评估]和CREDENCE[卡格列净与糖尿病合并肾病患者的肾脏事件之间关系的临床评价])、两项ns-MRA试验(FIDELIO...
SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
Few studies explored the effect of the combination of glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on the incidence of cardiovascular events in patients with type 2 diabetes (T2D) and acute myocardial infarction (AMI). Methods We re...
［摘要］回顾性总结5例门诊口服降糖药联合GLP-1受体激动剂（GLP-1RA ）治疗控制不佳，转换为德谷胰岛素利拉鲁肽注射液联合二甲双胍和（或）钠-葡萄糖共转运蛋白2（SGLT2）抑制剂的成人2型糖尿病（T2DM ）患者病例资料。随访发现，治疗1个月后患者空腹和餐后血糖均有明显改善，3个月时体重、腰围有一定程度的...
The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13:838277-. https://doi.org/10.3389/fphar.2022.838277. Gerstein HC, Sattar N, Rosenstock J, Rama...
SGLT2 inhibitorGLP‐1 analoguestype 2 diabetesweight lossThis study aimed to observe the effect of the novel combination of dual add-on therapy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on glycaemic control and weight in...
Background: The combination treatment of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1Ras) is increasing in clinical practice. We previously reported that the preceding drug did not influence the renal outcomes in patients with this ...